Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:36 AM
Ignite Modification Date:
2025-12-25 @ 4:36 AM
NCT ID:
NCT06187818
Eligibility Criteria:
Inclusion Criteria:
1. Female patients with breast cancer aged ≥ 20 years and ≤ 80 years, with informed consent and meeting the treatment standard of neoadjuvant chemotherapy scheme.
2. Patients who plan to receive neoadjuvant chemotherapy based on anthracycline drugs (such as erythromycin, doxorubicin, epirubicin, pyranomycin, idabicin, pentorubicin, and mitoxantrone).
3. No treatment for breast cancer before enrollment, such as chemotherapy, targeted therapy and endocrine therapy.
4. All patients underwent coarse needle biopsy of breast tumors (axillary lymph node biopsy is required for suspected axillary lymph node metastasis) to determine the status of ER, PR, HER-2, and Ki-67.
5. All patients have normal lung function, liver and kidney function.
Exclusion Criteria:
1. Cases that do not cooperate and are unwilling to sign informed consent forms.
2. Antitumor therapy, hormone replacement therapy and other breast cancer related treatments were performed before enrollment.
3. Merge any other malignant tumors.
4. Patients with poor image quality in echocardiography.
5. Continuous atrial fibrillation and severe arrhythmia affect ultrasound data collection and analysis.
6. Patients with active infections, a history of HIV, or chronic hepatitis B or C.
7. Patients with abnormal lung function or liver and kidney function.
8. Patients with hemorrhagic diseases.
9. Patients taking other heart protection traditional Chinese patent medicines and simple preparations.
10. Participated in other clinical researchers in the past 3 months.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
20 Years
Maximum Age:
80 Years
Study:
NCT06187818
Study Brief:
Protocol Section:
NCT06187818